Figure 5 | Leukemia

Figure 5

From: KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

Figure 5

KPT-8602 spares normal human hematopoietic stem and progenitor cells (HSPCs) engrafted into NSG mice. (a) Human CD45+ (hCD45+) cells per femur and tibia in normal human CD34+ grafts before and after treatment with vehicle or KPT-8602 for 4 weeks. (b) Percentage of hematopoietic stem and progenitor cells, hCD34+ and hCD34+/CD38− cells, in the BM of established grafts treated with vehicle or KPT-8602. (c) Normal HSC frequencies in grafts treated with vehicle, selinexor or KPT-8602 were obtained from analysis after transplantation into untreated secondary recipients. Fold reduction in HSC frequencies of selinexor or KPT-8602-treated grafts compared to vehicle-treated grafts. n=6−9 mice per group. Error bars represent mean±s.e.m.; ***P<0.0001 by Student’s t-test for comparison between the indicated groups. **P<0.001, ****P<0.0001.

Back to article page